We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+16.36%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$140M
AUM Growth
-$46.8M
Cap. Flow
-$52M
Cap. Flow %
-37.18%
Top 10 Hldgs %
57.92%
Holding
59
New
14
Increased
8
Reduced
12
Closed
24

Top Buys

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$14.4M
2
PCVX icon
Vaxcyte
PCVX
+$6M
3
VIR icon
Vir Biotechnology
VIR
+$5.82M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.13M
5
GMAB icon
Genmab
GMAB
+$5.02M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$18.8M
2
TERN
Terns Pharmaceuticals
TERN
+$17.9M
3
DVAX
Dynavax Technologies
DVAX
+$8.08M
4
URGN icon
UroGen Pharma
URGN
+$6.64M
5
COGT icon
Cogent Biosciences
COGT
+$5.21M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SMMT icon
1
Summit Therapeutics
SMMT
$10.7B
$16.9M 12.09%
+892,873
New +$14.4M
IMVT icon
2
Immunovant
IMVT
$8.27B
$8.88M 6.35%
357,606
+68,929
+24% +$1.78M
COGT icon
3
Cogent Biosciences
COGT
$6.68B
$8.67M 6.19%
225,158
-141,080
-39% -$5.21M
SVRA icon
4
Savara
SVRA
$1.13B
$8.66M 6.19%
1,585,977
+590,624
+59% +$3.29M
URGN icon
5
UroGen Pharma
URGN
$1.96B
$6.96M 4.98%
387,371
-330,983
-46% -$6.64M
DFTX
6
Definium Therapeutics
DFTX
$5.88B
$6.64M 4.75%
351,461
-73,741
-17% -$1.25M
VIR icon
7
Vir Biotechnology
VIR
$1.59B
$6.55M 4.68%
+730,548
New +$5.82M
PCVX icon
8
Vaxcyte
PCVX
$8.12B
$6.42M 4.59%
+110,454
New +$6M
CLDX icon
9
Celldex Therapeutics
CLDX
$2.77B
$5.71M 4.08%
180,048
+91,740
+104% +$2.5M
SION
10
Sionna Therapeutics
SION
$2.23B
$5.65M 4.04%
141,024
-39,569
-22% -$1.51M
GMAB icon
11
Genmab
GMAB
$17.6B
$5.28M 3.77%
196,709
+167,547
+575% +$5.02M
ZLAB icon
12
Zai Lab
ZLAB
$2.28B
$5.19M 3.71%
275,818
+78,965
+40% +$1.46M
VRTX icon
13
Vertex Pharmaceuticals
VRTX
$123B
$4.92M 3.51%
+11,010
New +$5.13M
IQV icon
14
IQVIA
IQV
$34.4B
$4.38M 3.13%
+25,668
New +$5.01M
MPLT
15
MapLight Therapeutics
MPLT
$1.72B
$3.91M 2.79%
+192,139
New +$3.44M
ARVN icon
16
Arvinas
ARVN
$517M
$3.31M 2.37%
+312,620
New +$3.87M
ORKA
17
Oruka Therapeutics
ORKA
$5.59B
$3.12M 2.23%
+63,591
New +$2.21M
UTHR icon
18
United Therapeutics
UTHR
$22.7B
$3.08M 2.2%
5,186
-4,265
-45% -$2.12M
TVTX icon
19
Travere Therapeutics
TVTX
$5.27B
$3.05M 2.18%
102,754
+64,732
+170% +$1.94M
TRVI icon
20
Trevi Therapeutics
TRVI
$2.71B
$3M 2.14%
251,566
+103,274
+70% +$1.16M
ANL
21
Adlai Nortye
ANL
$743M
$2.87M 2.05%
+414,852
New +$2.77M
CABA icon
22
Cabaletta Bio
CABA
$461M
$2.87M 2.05%
1,066,239
-1,187,311
-53% -$3.3M
PFE icon
23
Pfizer
PFE
$143B
$2.08M 1.48%
+74,000
New +$1.97M
AXSM icon
24
Axsome Therapeutics
AXSM
$11.8B
$1.9M 1.35%
11,217
-26,216
-70% -$4.53M
ORIC icon
25
Oric Pharmaceuticals
ORIC
$1.11B
$1.46M 1.04%
115,234
-140,136
-55% -$1.59M
1
2 3

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Superstring Capital Management held 59 positions worth $140M, down 25% from $187M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Superstring Capital Management withdrew a net $52M in Q1 2026, closing 24 positions and reducing 12 holdings. Its most notable exit was Cidara Therapeutics, an estimated $18.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Summit Therapeutics worth $16.9M.

  • Superstring Capital Management's largest Q1 2026 buy was Summit Therapeutics: 892,873 shares worth $16.9M.
  • Superstring Capital Management added most to Genmab in Q1 2026, an estimated $5.02M increase.
  • Superstring Capital Management's biggest Q1 2026 reduction was UroGen Pharma, cutting an estimated $6.64M.
  • Superstring Capital Management fully exited Cidara Therapeutics in Q1 2026, selling an estimated $18.8M.
  • Superstring Capital Management's ten largest holdings make up 58% of its $140M portfolio in Q1 2026.
  • Superstring Capital Management opened 14 new positions and closed 24 in Q1 2026.
  • Superstring Capital Management's portfolio value fell 25% quarter-over-quarter to $140M.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.